BidaskClub lowered shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a sell rating in a research note published on Friday, December 22nd.
Several other research analysts have also commented on the company. Cowen reiterated a buy rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. HC Wainwright boosted their price objective on Stemline Therapeutics from $34.00 to $38.00 and gave the company a buy rating in a research report on Wednesday, November 1st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $33.75.
Shares of Stemline Therapeutics (STML) traded up $0.25 on Friday, hitting $14.10. The stock had a trading volume of 100,595 shares, compared to its average volume of 217,680. The firm has a market cap of $356.55, a price-to-earnings ratio of -5.49 and a beta of -0.02. Stemline Therapeutics has a one year low of $5.50 and a one year high of $16.20.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 37,966 shares of company stock valued at $534,848 in the last quarter. 16.70% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Lyon Street Capital LLC raised its position in shares of Stemline Therapeutics by 331.1% during the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after purchasing an additional 415,867 shares during the period. Vanguard Group Inc. raised its position in shares of Stemline Therapeutics by 32.9% during the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock worth $7,055,000 after purchasing an additional 204,228 shares during the period. AXA raised its position in shares of Stemline Therapeutics by 44.9% during the second quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after purchasing an additional 195,022 shares during the period. C WorldWide Group Holding A S acquired a new stake in shares of Stemline Therapeutics during the third quarter worth $1,776,000. Finally, Artal Group S.A. raised its position in shares of Stemline Therapeutics by 150.0% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $2,300,000 after purchasing an additional 150,000 shares during the period. 50.24% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/01/13/stemline-therapeutics-stml-downgraded-by-bidaskclub-updated-updated.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.